Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Shima Moradi-kalbolandi"'
Autor:
Khadijeh Barzaman, Rana Vafaei, Mitra Samadi, Mohammad Hossein Kazemi, Aysooda Hosseinzadeh, Parnaz Merikhian, Shima Moradi-Kalbolandi, Mohammad Reza Eisavand, Houra Dinvari, Leila Farahmand
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-20 (2022)
Abstract As an intelligent disease, tumors apply several pathways to evade the immune system. It can use alternative routes to bypass intracellular signaling pathways, such as nuclear factor-κB (NF-κB), Wnt, and mitogen-activated protein (MAP)/phos
Externí odkaz:
https://doaj.org/article/a8b6d5a831aa4a8e97f6debab6334ed3
Autor:
Mitra Samadi, Keivan Majidzadeh-A, Malihe Salehi, Neda Jalili, Zeinab Noorinejad, Marjan Mosayebzadeh, Ahad Muhammadnejad, Azadeh Sharif khatibi, Shima Moradi-Kalbolandi, Leila Farahmand
Publikováno v:
Journal of Biological Engineering, Vol 15, Iss 1, Pp 1-15 (2021)
Abstract Development of engineered non-pathogenic bacteria, capable of expressing anti-cancer proteins under tumor-specific conditions, is an ideal approach for selectively eradicating proliferating cancer cells. Herein, using an engineered hypoxia r
Externí odkaz:
https://doaj.org/article/df436bf75895436a9d27c963b6ecc759
Autor:
Mitra Samadi, Keivan Majidzadeh-A, Malihe Salehi, Neda Jalili, Zeinab Noorinejad, Marjan Mosayebzadeh, Ahad Muhammadnejad, Azadeh Sharif Khatibi, Shima Moradi-Kalbolandi, Leila Farahmand
Publikováno v:
Journal of Biological Engineering, Vol 16, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/48e84a016f074a7da903aebbd5abc1be
Autor:
Shima Moradi-Kalbolandi, Mahdi Habibi-Anbouhi, Majid Golkar, Mahdi Behdani, Gashin Rezaei, Leila Ghazizadeh, Mohsen Abolhassani, Mohammad Ali Shokrgozar
Publikováno v:
Data in Brief, Vol 8, Iss , Pp 1137-1143 (2016)
Current therapies for acute myeloid leukemia (AML), are associated with high relapse rates. Hence, development of new therapeutic strategies is crucial to circumvent this problem. Bivalent antibody technology has been used to engineer novel antibody
Externí odkaz:
https://doaj.org/article/a9b8445334c941bdba3ac35eaef04e6a
Autor:
Rana Vafaei, Zohreh Khaki, Malihe Salehi, Neda Jalili, Mohammad Reza Esmailinejad, Ahad Muhammadnajad, Seyed Mahdi Nassiri, Alireza Vajhi, Shima Moradi Kalbolandi, Roya Mirzaei, Leila Farahmand
Publikováno v:
Investigational New Drugs. 41:226-239
The usage of monoclonal antibodies (mAbs), as a matter associated with the biopharmaceutical industry, is increasingly growing. Harmonious with this concept, we designed the exquisitely modeled anti-MET scFv against breast cancer by gene cloning, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7435e31cc35bdb36db14cd9eb2081861
https://doi.org/10.1007/s10637-023-01354-7
https://doi.org/10.1007/s10637-023-01354-7
Autor:
Farnaz Khodabakhsh, Shima Shokri, Neda Jalili, Shima Moradi-Kalbolandi, Fariba Dashtestani, Leila Farahmand
Publikováno v:
Chemical Papers. 77:2229-2235
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c08041fc5bdf587491a553c15baf516
https://doi.org/10.1007/s11696-022-02625-y
https://doi.org/10.1007/s11696-022-02625-y
Autor:
Keyvan Majidzadeh-A, Leila Farahmand, Neda Jalili, Shima Moradi-Kalbolandi, Mohadeseh Haji Abdolvahab
Publikováno v:
Probiotics and Antimicrobial Proteins
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing the 2019 novel coronavirus disease (COVID-19), was introduced by WHO (World Health Organization) as "pandemic" in March 2020. According to WHO, thus far (23 November 2020) 58,425,68
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13d6b2adaa60593c733dd8b2e1b7c78
https://doi.org/10.1007/s12602-021-09773-9
https://doi.org/10.1007/s12602-021-09773-9
Publikováno v:
Engineering in Life Sciences
Escherichia coli is one of the most suitable hosts for production of antibodies and antibody fragments. Antibody fragment secretion to the culture medium improves product purity in cell culture and diminishes downstream costs. In this study, E. coli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d478e53dd542ce84bb398f2c03a669a6
http://europepmc.org/articles/PMC7401236
http://europepmc.org/articles/PMC7401236
Autor:
Leila Farahmand, Keivan Majidzadeh-A, Neda Jalili, Saeedeh Boroumandieh, Behrad Darvishi, Shima Moradi-Kalbolandi, Malihe Salehi
Publikováno v:
Cell Biochemistry and Function. 38:651-659
It has been shown that overexpression of activated leukocyte cell adhesion molecule (ALCAM) is involved in development of resistance to tamoxifen therapy and promotion of cell invasion, migration and metastasis in ER+ breast cancer cells. Thus, we hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1703282d025b95b8fcf98e9487c943f7
https://doi.org/10.1002/cbf.3525
https://doi.org/10.1002/cbf.3525
Autor:
Marjan Mosayebzadeh, Malihe Salehi, Neda Jalili, Solmaz Sadeghi, Keivan Majidzadeh-A, Leila Farahmand, Shima Moradi-Kalbolandi, Azadeh Sharifi-K, Behrad Darvishi, Hassan Sanati
Publikováno v:
Molecular Immunology. 118:174-181
T cells are the most predominant effector cells in immune-mediated elimination of cancer and circumventing tumor progression. Among various approaches, T cells activation by specific antibodies independently of their TCR specificity, is considered as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad28378da4de9d64114ffef7587b65b6
https://doi.org/10.1016/j.molimm.2019.12.017
https://doi.org/10.1016/j.molimm.2019.12.017